Welcome to our dedicated page for Autolus Therapeutics plc SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autolus Therapeutics plc filings document a foreign-issuer ADS structure and material events for a commercial-stage T cell therapy company. The company’s American Depositary Shares trade on the Nasdaq Global Select Market, with each ADS representing one ordinary share, while the ordinary shares are registered in connection with the ADS listing.
Recent Form 8-K disclosures cover financial results, corporate presentations, AUCATZYL revenue updates, pipeline and manufacturing matters, and a master service agreement for lentiviral vector supply used in CAR-T products. The filings also record operational efficiency costs, changes in the company’s independent registered public accounting firm, internal-control disclosures, executive and compensation matters, governance actions and Regulation FD materials.
Autolus Therapeutics plc director William D. Young received equity-based compensation awards. On June 29, 2026, he was granted options to purchase 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He was also granted 31,667 restricted share units, each representing one American Depositary Share, vesting in a single installment on June 29, 2027. Following these awards, his reported holdings in these instruments match the granted amounts.
Autolus Therapeutics plc director Rao Madduri Ravin received new equity awards in the form of options and restricted share units tied to American Depositary Shares. The grant includes 47,500 share options with a $1.61 exercise price expiring on June 29, 2036, and 31,667 restricted share units. The RSUs vest in a single installment on June 29, 2027, while the options vest in twelve equal monthly installments starting on July 29, 2026. These awards represent compensation-related acquisitions rather than open-market purchases or sales.
Autolus Therapeutics plc director Ryan Richardson received new equity awards in the form of options and restricted share units. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, expiring on June 29, 2036. These options vest in twelve equal monthly installments starting on July 29, 2026. He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. Following these grants, his reported holdings for these awards match the granted amounts, reflecting compensation rather than open‑market trading.
Autolus Therapeutics plc director Elisabeth Leiderman received new equity awards. She was granted options over 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026, and 31,667 restricted share units that vest in one installment on June 29, 2027. Each RSU represents a right to receive one American Depositary Share, and each American Depositary Share is convertible into one Ordinary Share.
Autolus Therapeutics plc director Robert Iannone received new equity awards. He was granted options covering 47,500 American Depositary Shares at an exercise price of $1.6100 per share, vesting in twelve equal monthly installments starting on July 29, 2026, and expiring on June 29, 2036.
He also received 31,667 restricted share units, each representing one American Depositary Share, which will vest in a single installment on June 29, 2027. Each American Depositary Share is convertible into one ordinary share of Autolus Therapeutics.
Autolus Therapeutics plc director Cynthia M. Butitta received new equity awards. She was granted options to buy 47,500 shares of American Depositary Shares at an exercise price of $1.61 per share, expiring on June 29, 2036, vesting in twelve equal monthly installments starting July 29, 2026.
She also received 31,667 restricted share units, each representing one American Depositary Share, vesting in a single installment on June 29, 2027. These awards are compensation-related grants rather than open‑market purchases or sales.
Autolus Therapeutics plc director Linda Bain received new equity awards as part of her compensation. She was granted a share option covering 47,500 American Depositary Shares with an exercise price of $1.61 per share, expiring on June 29, 2036. These options vest in twelve equal monthly installments starting on July 29, 2026.
She also received 31,667 restricted share units, each representing a contingent right to one American Depositary Share. The RSUs vest in a single installment on June 29, 2027. Each American Depositary Share is convertible at any time into one ordinary share, providing future potential ownership if the awards vest and, for options, are exercised.
Autolus Therapeutics plc director Robert Azelby received new equity awards in the form of options and restricted share units tied to the company’s American Depositary Shares. On June 29, 2026, he was granted options over 47,500 ADSs at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting July 29, 2026. He also received 31,667 restricted share units covering 31,667 ADSs, which vest in a single installment on June 29, 2027. Each RSU represents a contingent right to receive one ADS, and each ADS is convertible into one ordinary share.
Autolus Therapeutics plc director Michael W. Bonney received new equity-based compensation. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. These awards increase his potential future ownership but are subject to time-based vesting.
Autolus Therapeutics plc reported the results of its 2026 Annual General Meeting held on June 29, 2026. Shareholders approved all six ordinary resolutions presented at the meeting.
They received and adopted the 2025 Annual Report and Accounts, with 165,846,326 votes for and 2,895,344 against. The directors’ remuneration report was approved with 156,192,216 votes for and 12,502,946 against. Ernst & Young LLP (US) was appointed as auditors, receiving 165,871,368 votes in favor and 2,872,225 against.
Shareholders also re-elected three directors. Mr. M Bonney was re-elected with 165,491,394 votes for and 3,312,126 against. Dr. E Leiderman was re-elected with 165,741,204 votes for and 3,063,838 against. Mr. R W Azelby was re-elected with 162,133,091 votes for and 6,671,776 against.